1: The metabolism of drug2 can be increased when combined with drug1.
1: The metabolism of drug1 can be increased when combined with drug2.
2: The risk or severity of adverse effects can be increased when drug2 is combined with drug1.
2: The risk or severity of adverse effects can be increased when drug1 is combined with drug2.
3: drug1 may decrease the excretion rate of drug2 which could result in a higher serum level.
3: drug2 may decrease the excretion rate of drug1 which could result in a higher serum level.
4: The therapeutic efficacy of drug1 can be decreased when used in combination with drug2.
4: The therapeutic efficacy of drug2 can be decreased when used in combination with drug1.
5: The risk or severity of hypoglycemia can be increased when drug2 is combined with drug1.
5: The risk or severity of hypoglycemia can be increased when drug1 is combined with drug2.
6: The serum concentration of drug1 can be increased when it is combined with drug2.
6: The serum concentration of drug2 can be increased when it is combined with drug1.
7: The risk or severity of bleeding can be increased when drug2 is combined with drug1.
7: The risk or severity of bleeding can be increased when drug1 is combined with drug2.
8: The metabolism of drug2 can be decreased when combined with drug1.
8: The metabolism of drug1 can be decreased when combined with drug2.
9: The risk or severity of methemoglobinemia can be increased when drug1 is combined with drug2.
9: The risk or severity of methemoglobinemia can be increased when drug2 is combined with drug1.
10: drug2 may increase the thrombogenic activities of drug1.
10: drug1 may increase the thrombogenic activities of drug2.
11: The therapeutic efficacy of drug1 can be increased when used in combination with drug2.
11: The therapeutic efficacy of drug2 can be increased when used in combination with drug1.
12: The risk or severity of hyperglycemia can be increased when drug2 is combined with drug1.
12: The risk or severity of hyperglycemia can be increased when drug1 is combined with drug2.
13: The risk or severity of bleeding and hemorrhage can be increased when drug2 is combined with drug1.
13: The risk or severity of bleeding and hemorrhage can be increased when drug1 is combined with drug2.
14: The risk or severity of QTc prolongation can be increased when drug1 is combined with drug2.
14: The risk or severity of QTc prolongation can be increased when drug2 is combined with drug1.
15: The risk or severity of CNS depression can be increased when drug1 is combined with drug2.
15: The risk or severity of CNS depression can be increased when drug2 is combined with drug1.
16: drug2 may increase the hypoglycemic activities of drug1.
16: drug1 may increase the hypoglycemic activities of drug2.
17: The risk or severity of Thrombosis can be increased when drug2 is combined with drug1.
17: The risk or severity of Thrombosis can be increased when drug1 is combined with drug2.
18: drug1 may increase the excretion rate of drug2 which could result in a lower serum level and potentially a reduction in efficacy.
18: drug2 may increase the excretion rate of drug1 which could result in a lower serum level and potentially a reduction in efficacy.
19: drug2 may increase the immunosuppressive activities of drug1.
19: drug1 may increase the immunosuppressive activities of drug2.
20: drug1 may increase the hypotensive activities of drug2.
20: drug2 may increase the hypotensive activities of drug1.
21: drug1 may decrease the hypoglycemic activities of drug2.
21: drug2 may decrease the hypoglycemic activities of drug1.
22: The risk or severity of immunosuppression can be increased when drug1 is combined with drug2.
22: The risk or severity of immunosuppression can be increased when drug2 is combined with drug1.
23: drug2 may increase the anticoagulant activities of drug1.
23: drug1 may increase the anticoagulant activities of drug2.
24: The risk or severity of neutropenia can be increased when drug1 is combined with drug2.
24: The risk or severity of neutropenia can be increased when drug2 is combined with drug1.
25: The risk or severity of angioedema can be increased when drug1 is combined with drug2.
25: The risk or severity of angioedema can be increased when drug2 is combined with drug1.
26: The risk or severity of infection can be increased when drug2 is combined with drug1.
26: The risk or severity of infection can be increased when drug1 is combined with drug2.
27: The serum concentration of drug2 can be decreased when it is combined with drug1.
27: The serum concentration of drug1 can be decreased when it is combined with drug2.
28: The risk or severity of neutropenia and thrombocytopenia can be increased when drug2 is combined with drug1.
28: The risk or severity of neutropenia and thrombocytopenia can be increased when drug1 is combined with drug2.
29: drug1 may increase the bradycardic activities of drug2.
29: drug2 may increase the bradycardic activities of drug1.
30: The risk or severity of hemorrhage can be increased when drug2 is combined with drug1.
30: The risk or severity of hemorrhage can be increased when drug1 is combined with drug2.
31: drug2 may decrease the anticoagulant activities of drug1.
31: drug1 may decrease the anticoagulant activities of drug2.
32: drug1 may increase the myelosuppressive activities of drug2.
32: drug2 may increase the myelosuppressive activities of drug1.
33: The risk or severity of myelosuppression can be increased when drug2 is combined with drug1.
33: The risk or severity of myelosuppression can be increased when drug1 is combined with drug2.
34: drug2 may increase the gastrointestinal motility reducing activities of drug1.
34: drug1 may increase the gastrointestinal motility reducing activities of drug2.
35: The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug1 is combined with drug2.
35: The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug2 is combined with drug1.
36: The risk or severity of cardiotoxicity can be increased when drug1 is combined with drug2.
36: The risk or severity of cardiotoxicity can be increased when drug2 is combined with drug1.
37: The risk or severity of bleeding and bruising can be increased when drug1 is combined with drug2.
37: The risk or severity of bleeding and bruising can be increased when drug2 is combined with drug1.
38: drug2 can cause a decrease in the absorption of drug1 resulting in a reduced serum concentration and potentially a decrease in efficacy.
39: The risk or severity of gastrointestinal irritation can be increased when drug2 is combined with drug1.
38: drug1 can cause a decrease in the absorption of drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.
39: The risk or severity of gastrointestinal irritation can be increased when drug1 is combined with drug2.
40: drug2 may increase the orthostatic hypotensive activities of drug1.
40: drug1 may increase the orthostatic hypotensive activities of drug2.
41: The risk or severity of myopathy and weakness can be increased when drug1 is combined with drug2.
41: The risk or severity of myopathy and weakness can be increased when drug2 is combined with drug1.
42: The risk or severity of Cardiac Arrhythmia can be increased when drug1 is combined with drug2.
42: The risk or severity of Cardiac Arrhythmia can be increased when drug2 is combined with drug1.
43: drug1 may increase the central nervous system depressant (CNS depressant) activities of drug2.
43: drug2 may increase the central nervous system depressant (CNS depressant) activities of drug1.
44: The serum concentration of the active metabolites of drug2 can be reduced when drug2 is used in combination with drug1 resulting in a loss in efficacy.
44: The serum concentration of the active metabolites of drug1 can be reduced when drug1 is used in combination with drug2 resulting in a loss in efficacy.
45: The risk or severity of peripheral neuropathy can be increased when drug1 is combined with drug2.
45: The risk or severity of peripheral neuropathy can be increased when drug2 is combined with drug1.
46: The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when drug1 is combined with drug2.
46: The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when drug2 is combined with drug1.
47: drug1 may increase the neuromuscular blocking activities of drug2.
47: drug2 may increase the neuromuscular blocking activities of drug1.
48: The risk or severity of hypokalemia can be increased when drug2 is combined with drug1.
48: The risk or severity of hypokalemia can be increased when drug1 is combined with drug2.
49: The risk or severity of hypertension can be increased when drug1 is combined with drug2.
50: drug1 can cause an increase in the absorption of drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.
49: The risk or severity of hypertension can be increased when drug2 is combined with drug1.
50: drug2 can cause an increase in the absorption of drug1 resulting in an increased serum concentration and potentially a worsening of adverse effects.
51: The risk or severity of hypotension can be increased when drug2 is combined with drug1.
51: The risk or severity of hypotension can be increased when drug1 is combined with drug2.
52: drug2 may decrease the cardiotoxic activities of drug1.
53: The absorption of drug1 can be decreased when combined with drug2.
52: drug1 may decrease the cardiotoxic activities of drug2.
53: The absorption of drug2 can be decreased when combined with drug1.
54: drug2 may increase the antiplatelet activities of drug1.
54: drug1 may increase the antiplatelet activities of drug2.
55: The risk or severity of tendinopathy can be increased when drug2 is combined with drug1.
55: The risk or severity of tendinopathy can be increased when drug1 is combined with drug2.
56: The risk or severity of hypocalcemia can be increased when drug1 is combined with drug2.
56: The risk or severity of hypocalcemia can be increased when drug2 is combined with drug1.
57: drug2 may decrease the antihypertensive activities of drug1.
57: drug1 may decrease the antihypertensive activities of drug2.
58: drug1 may increase the vasoconstricting activities of drug2.
58: drug2 may increase the vasoconstricting activities of drug1.
59: The risk or severity of edema formation can be increased when drug1 is combined with drug2.
59: The risk or severity of edema formation can be increased when drug2 is combined with drug1.
60: The risk or severity of gastrointestinal bleeding can be increased when drug1 is combined with drug2.
60: The risk or severity of gastrointestinal bleeding can be increased when drug2 is combined with drug1.
61: The risk or severity of pulmonary toxicity can be increased when drug1 is combined with drug2.
61: The risk or severity of pulmonary toxicity can be increased when drug2 is combined with drug1.
62: The risk or severity of electrolyte imbalance can be increased when drug2 is combined with drug1.
62: The risk or severity of electrolyte imbalance can be increased when drug1 is combined with drug2.
63: The risk or severity of congestive heart failure can be increased when drug1 is combined with drug2.
64: The risk of a hypersensitivity reaction to drug2 is increased when it is combined with drug1.
65: drug1 may increase the sedative activities of drug2.
66: The risk or severity of respiratory depression can be increased when drug2 is combined with drug1.
65: drug2 may increase the sedative activities of drug1.
64: The risk of a hypersensitivity reaction to drug1 is increased when it is combined with drug2.
63: The risk or severity of congestive heart failure can be increased when drug2 is combined with drug1.
66: The risk or severity of respiratory depression can be increased when drug1 is combined with drug2.
67: drug1 may increase the QTc-prolonging activities of drug2.
67: drug2 may increase the QTc-prolonging activities of drug1.
68: drug1 may increase the hepatotoxic activities of drug2.
68: drug2 may increase the hepatotoxic activities of drug1.
69: The risk or severity of anemia can be increased when drug1 is combined with drug2.
70: The risk or severity of orthostatic hypotension and syncope can be increased when drug1 is combined with drug2.
71: The risk or severity of hypotension and orthostatic hypotension can be increased when drug1 is combined with drug2.
72: The risk or severity of sedation, somnolence, and CNS depression can be increased when drug2 is combined with drug1.
73: The risk or severity of sedation can be increased when drug2 is combined with drug1.
72: The risk or severity of sedation, somnolence, and CNS depression can be increased when drug1 is combined with drug2.
74: drug2 may increase the hypokalemic activities of drug1.
70: The risk or severity of orthostatic hypotension and syncope can be increased when drug2 is combined with drug1.
73: The risk or severity of sedation can be increased when drug1 is combined with drug2.
75: The risk or severity of fluid retention can be increased when drug2 is combined with drug1.
69: The risk or severity of anemia can be increased when drug2 is combined with drug1.
71: The risk or severity of hypotension and orthostatic hypotension can be increased when drug2 is combined with drug1.
74: drug1 may increase the hypokalemic activities of drug2.
75: The risk or severity of fluid retention can be increased when drug1 is combined with drug2.
76: The risk or severity of liver damage can be increased when drug1 is combined with drug2.
77: The risk or severity of increased transaminases can be increased when drug2 is combined with drug1.
78: The risk or severity of bradycardia can be increased when drug2 is combined with drug1.
76: The risk or severity of liver damage can be increased when drug2 is combined with drug1.
77: The risk or severity of increased transaminases can be increased when drug1 is combined with drug2.
78: The risk or severity of bradycardia can be increased when drug1 is combined with drug2.
79: The risk or severity of thromboembolism can be increased when drug2 is combined with drug1.
80: The risk or severity of adverse effects can be decreased when drug2 is combined with drug1.
81: The risk or severity of sedation and CNS depression can be increased when drug2 is combined with drug1.
82: The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when drug1 is combined with drug2.
83: drug1 may increase the hypertensive activities of drug2.
84: The risk or severity of bleeding and thrombocytopenia can be increased when drug1 is combined with drug2.
83: drug2 may increase the hypertensive activities of drug1.
85: The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when drug2 is combined with drug1.
86: The risk or severity of QTc prolongation and torsade de pointes can be increased when drug2 is combined with drug1.
81: The risk or severity of sedation and CNS depression can be increased when drug1 is combined with drug2.
79: The risk or severity of thromboembolism can be increased when drug1 is combined with drug2.
80: The risk or severity of adverse effects can be decreased when drug1 is combined with drug2.
85: The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when drug1 is combined with drug2.
86: The risk or severity of QTc prolongation and torsade de pointes can be increased when drug1 is combined with drug2.
82: The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when drug2 is combined with drug1.
84: The risk or severity of bleeding and thrombocytopenia can be increased when drug2 is combined with drug1.
87: The serum concentration of dextroamphetamine, an active metabolite of drug2, can be increased when used in combination with drug1.
88: The risk or severity of confusion, irritability, and sleep disorders can be increased when drug1 is combined with drug2.
89: drug1 may increase the cardiotoxic activities of drug2.
90: drug1 may increase the nephrotoxic activities of drug2.
91: The risk or severity of neuromuscular blockade can be increased when drug2 is combined with drug1.
92: drug2 may increase the uterotonic activities of drug1.
92: drug1 may increase the uterotonic activities of drug2.
90: drug2 may increase the nephrotoxic activities of drug1.
93: The risk or severity of leukopenia can be increased when drug2 is combined with drug1.
89: drug2 may increase the cardiotoxic activities of drug1.
91: The risk or severity of neuromuscular blockade can be increased when drug1 is combined with drug2.
87: The serum concentration of dextroamphetamine, an active metabolite of drug1, can be increased when used in combination with drug2.
94: The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when drug1 is combined with drug2.
95: The risk or severity of ulceration can be increased when drug1 is combined with drug2.
94: The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when drug2 is combined with drug1.
96: The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when drug1 is combined with drug2.
96: The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when drug2 is combined with drug1.
93: The risk or severity of leukopenia can be increased when drug1 is combined with drug2.
88: The risk or severity of confusion, irritability, and sleep disorders can be increased when drug2 is combined with drug1.
95: The risk or severity of ulceration can be increased when drug2 is combined with drug1.
